Surveillance May Reduce CIN 2 Overtreatment

Overview

A target trial emulation indicates that surveillance for cervical intraepithelial neoplasia grade 2 (CIN 2) may decrease unnecessary excisions. Immediate treatment did not show lower risks for cervical cancer or CIN 3+ compared to delayed treatment.

Background

Cervical intraepithelial neoplasia grade 2 is a common diagnosis that can lead to overtreatment, including unnecessary excisions. This study provides insights into management strategies that could reduce overtreatment in selected patients.

Data Highlights

Key Findings

• Immediate treatment of CIN 2 was not associated with lower 3-year risks for cervical cancer or CIN 3+ compared to delayed treatment.
• 36% of patients undergoing immediate treatment had excision specimens showing less severe disease than CIN 2.
• The estimated 3-year probability of potentially unnecessary excision was 45% for immediate treatment in lower-risk patients.
• Patients with HPV types 16 or 18 positivity had higher risks for CIN 3+ regardless of management strategy.
• Delayed treatment may be a viable option for selected patients, particularly those with lower-risk antecedent screening results.

Clinical Implications

Risk stratification based on antecedent screening results can guide treatment decisions.

Conclusion

The findings indicate that delaying treatment for CIN 2 may reduce unnecessary excisions without significantly increasing the risk of cervical cancer or CIN 3+ over a 3-year period.

Related Resources & Content

1. Cheung LC, et al., Annals of Internal Medicine, 2023 -- Surveillance May Reduce CIN 2 Overtreatment
2. The ASCO Post — Extended Active Surveillance Prior to Systemic Therapy May Be Safe in Some Patients With Metastatic Renal Cell Carcinoma
3. The ASCO Post — Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer
4. The New Gastroenterologist — Subsequent Surveillance Risk is Influenced by Previous Colonoscopy Findings
5. The ASCO Post — Rates of Active Surveillance Rising Among Men With Low-Risk Prostate Cancer but Still Suboptimal
6. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors - PMC
7. Active surveillance of cervical intraepithelial neoplasia grade 2: 2025 British Society of Colposcopy and Cervical Pathology and European Society of Gynaecologic Oncology consensus statement - ScienceDirect
8. 2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023 - PMC
9. Enduring Consensus Cervical Cancer Screening and Management Guidelines - NCI
10. Updated Guidelines for Management of Cervical Cancer Screening Abnormalities | ACOG
11. Adjuvant Human Papillomavirus Vaccination for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia 2+ | ACOG
12. OPEN ACCESS
13. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis | The BMJ
14. Untreated cervical intraepithelial neoplasia grade 2 and subsequent risk of cervical cancer: population based cohort study | The BMJ
15. Preterm Birth Following Surveillance vs Loop Excision for CIN2